Literature DB >> 16043123

Highly specific expression of luciferase gene in lungs of naïve nude mice directed by prostate-specific antigen promoter.

Hong-Wei Li1, Jinzhong Li, Gregory A Helm, Dongfeng Pan.   

Abstract

PSA promoter has been demonstrated the utility for tissue-specific toxic gene therapy in prostate cancer models. Characterization of foreign gene overexpression in normal animals elicited by PSA promoter should help evaluate therapy safety. Here we constructed an adenovirus vector (AdPSA-Luc), containing firefly luciferase gene under the control of the 5837 bp long prostate-specific antigen promoter. A charge coupled device video camera was used to non-invasively image expression of firefly luciferase in nude mice on days 3, 7, 11 after injection of 2 x 10(9)PFU of AdPSA-Luc virus via tail vein. The result showed highly specific expression of the luciferase gene in lungs of mice from day 7. The finding indicates the potential limitations of the suicide gene therapy of prostate cancer based on selectivity of PSA promoter. By contrary, it has encouraging implications for further development of vectors via PSA promoter to enable gene therapy for pulmonary diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16043123     DOI: 10.1016/j.bbrc.2005.07.025

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Functional characterization of the GDEP promoter and three enhancer elements in retinoblastoma and prostate cell lines.

Authors:  D S Cross; J K Burmester
Journal:  Med Oncol       Date:  2007-06-27       Impact factor: 3.064

2.  Effects of angiotensin II type 2 receptor overexpression on the growth of hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Hongyan Du; Zhibing Liang; Yanling Zhang; Feilong Jie; Jinlong Li; Yang Fei; Zhi Huang; Nana Pei; Suihai Wang; Andrew Li; Baihong Chen; Yi Zhang; Colin Sumners; Ming Li; Hongwei Li
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.